Esophageal Cancer Clinical Trial
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.
Primary Objective: To determine whether the Serious Illness Conversation Guide will improve the consistency with which providers have and document conversations regarding patients' goals and priorities as they near the end of life.
Secondary Objectives: 1. To assess whether having conversations as per this model will improve the quality of care near the end of life as determined by appropriate care in concordance with their goals of care.
2. To assess whether having conversations as per this model will improve patient Quality of Life (QOL) as per a validated scale.
3. To assess in patients with concordant care whether this model will improve patient QOL as per a validated scale 4. To assess provider opinions about end-of-life conversations.
Patients with metastatic colorectal cancer whose tumor has progressed on both FOLFOX and FOLFIRI.
Exception: Patients with metastatic colorectal cancer whose tumors demonstrate a BRAF V600E mutation may be enrolled regardless of prior chemotherapy.
Exception: Patients whose tumors are MSI-H must have experience progression through immunotherapy in addition to the therapies mentioned above.
Patients with metastatic pancreatic adenocarcinoma.
Patients with metastatic gastric or esophageal cancer whose tumor has progressed through first-line chemotherapy of any type.
Patients with metastatic cholangiocarcinoma whose tumor has progressed through first-line chemotherapy of any type.
Patients with metastatic hepatocellular carcinoma whose tumor has progressed through PD1 blockade.
Patients with metastatic high-grade neuroendocrine tumor.
A patient with a metastatic GIST that has progressed through first-line tyrosine kinase inhibitor.
Expected life expectancy of at least one month
Any patient not meeting the above criteria
Non-English speaking patients
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Stanford California, 94304, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.